Page 4 - Cadila Healthcare

Cadila to make India's first indigenous antibody test kit: Health Minister

The anti-SARS-Cov-2 human lgG ELISA kit has the advantage of testing 90 samples together in a single run of 2.5 hours

Nifty needs to hold 9,150 for further up move: Nilesh Jain of Anand Rathi

Nifty is currently near its previous swing low which is placed at 9,150

In race to stop Covid-19, Indian drugmakers to conduct clinical trials

Glenmark, Zydus Cadila to start trials in May

Cadila Healthcare at the forefront, looks at biologic drug to treat Covid

Company is already working on developing 2 vaccine candidates, diagnostic kits and also making HCQ

Multiple growth levers make Cadila Healthcare attractive on the Street

HCQ supplies for Covid-19 treatment to propel US growth, even as domestic pharma and consumer businesses are in a sweet spot

Cadila Healthcare soars 31% in 2 days on USFDA nod for Perphenazine tablets

Zydus Cadila has received final approval from the United States Food and Drug Administration to market Perphenazine tablets USP, 2 mg, 4 mg, 8 mg and 16 mg

Speeding up the cure

Drug regulators must work to compress timeline for trials

Ipca and Cadila Healthcare gear up to make drug for coronavirus

Ipca is the biggest producer of the drug. Cadila Healthcare, based in Ahmedabad, too is a major player

Cadila board approves transfer of animal healthcare arm to Zydus Health

The transfer of animal healthcare business is through execution of a definitive agreement, Cadila Healthcare said in a filing to BSE

Zydus Cadila launches research programme to develop vaccine for coronavirus

The epidemic, which was detected last December, has claimed around 1,500 lives and infected over 66,000 people.

Stock recommendation from Prabhudas Lilladher: Buy ACC, Cadila Health

For ACC, the RSI has signaled a trend reversal while decent volume participation has also been witnessed

USFDA completes inspection of Cadila Healthcare's Ahmedabad facility

Shares of Cadila Healthcare closed at Rs 264.05 per scrip on the BSE, up 1.46 per cent from its previous close

Cadila gains after USFDA concludes plant inspection with no observations

The United States Food and Drug Administration (USFDA) inspected the company's topical manufacturing facility in Ahmedabad during December 16-20, 2019, the drug firm said in a BSE filing.

Cadila Healthcare pays Rs 1.62 cr for full ownership of Zydus Technologies

Posts 77% dip in consolidated profit before tax for Q2 of FY20

Cadila growth may take a hit as Moraiya facility comes under USFDA radar

Krishnanath Munde at Reliance Securities says he does not expect any new drug approval from the facility till it gets regulatory clearance.

Cadila Healthcare dips 8% as USFDA issues warning letter for Moraiya plant

The company said the warning letter does not affect the existing business of the company in the US and the existing product supplies from the Moraiya facility will continue.

USFDA issues warning letter for Cadila Healthcare's Moraiya facility

The formulation unit 45% of the firm's US sales; Cadila says letter does not impact its existing business in the United States for now

Cadila Healthcare receives US FDA approval for schizophrenia drug

The product will be manufactured at Liva Pharma's manufacturing facility at Vadodara

Nifty Outlook and top trading ideas by CapitalVia Global Research Limited

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

Cadila Healthcare recovers on India, emerging market sales forecast

Restructuring and consumer acquisition to be key drivers of revenue